GU Cancers 2019 | Atezolizumab plus bevacizumab in non-clear cell, sarcomatoid kidney cancer

Rana McKay

Rana McKay, MD, of the University of California San Diego, San Diego, CA, speaks at the 2019 Genitourinary Cancers Symposium, held in San Francisco, CA. In the Phase II, open-label, single-arm study (NCT02724878), Dr Rana McKay and colleagues investigated the efficacy and safety of the combined use of atezolizumab and bevacizumab in non-clear cell and sarcomatoid differentiation RCC. She reports that promising anti-tumor activity was shown in the treated patients, in addition to a tolerable safety profile.

Share this video